Detalhe da pesquisa
1.
Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease.
Haematologica
; 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38205523
2.
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
Cancer
; 129(16): 2491-2498, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37282609
3.
The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.
Br J Haematol
; 198(2): 307-316, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35507638
4.
Gastrointestinal, hepatic, and pancreatobiliary involvement by plasma cell neoplasms: clinicopathologic correlations in a retrospective cohort of 116 cases.
Histopathology
; 81(6): 742-757, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35984728
5.
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.
Haematologica
; 2021 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34382384
6.
Combinatorial treatment for unresectable unicentric Castleman disease.
Eur J Haematol
; 107(4): 484-488, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34242421
7.
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
PLoS Med
; 17(11): e1003323, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33147277
8.
Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease.
J Oncol Pharm Pract
; 26(5): 1128-1133, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31795821
9.
Ongoing symptoms following complete surgical excision in unicentric Castleman disease.
Am J Hematol
; 98(11): E334-E337, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37635628
10.
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
Am J Hematol
; 97(6): E195-E198, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35285981
11.
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.
Haematologica
; 106(12): 3215-3218, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34847659
12.
Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma.
Am J Hematol
; 96(9): E341-E344, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34050985
13.
CLL/SLL with initial presentation as a longstanding cutaneous plaque: a rare case.
J Cutan Pathol
; 43(8): 717-21, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27147484
14.
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.
Blood Adv
; 8(3): 703-707, 2024 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38052037
15.
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.
Cancers (Basel)
; 16(6)2024 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38539451
16.
A case of acquired dysfibrinogenemia in multiple myeloma treated with therapeutic plasma exchange.
Transfus Apher Sci
; 48(1): 35-8, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22842111
17.
EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression.
Cancers (Basel)
; 15(18)2023 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37760488
18.
Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
Blood Adv
; 7(21): 6652-6664, 2023 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37656441
19.
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma.
Cell Rep Med
; 4(10): 101214, 2023 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37794587
20.
The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma.
Haematologica
; 102(9): e364-e367, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28550191